• Je něco špatně v tomto záznamu ?

Fertility-Preserving Treatments and Patient- and Parental Satisfaction on Fertility Counseling in a Cohort of Newly Diagnosed Boys and Girls with Childhood Hodgkin Lymphoma

KCE. Drechsel, IM. IJgosse, S. Slaats, L. Raasen, FS. Stoutjesdijk, E. van Dulmen-den Broeder, WH. Wallace, A. Beishuizen, D. Körholz, C. Mauz-Körholz, M. Cepelova, A. Uyttebroeck, L. Ronceray, GJL. Kaspers, SL. Broer, MA. Veening, EuroNet-PHL-C2...

. 2024 ; 16 (11) : . [pub] 20240531

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012662

Grantová podpora
project 257 Foundation KiKa

PURPOSE: The purpose of this study is to evaluate the use of fertility-preserving (FP) treatments and fertility counseling that was offered in a cohort of newly diagnosed children with classical Hodgkin lymphoma (cHL). METHODS: In this observational study, boys and girls with cHL aged ≤ 18 years with scheduled treatment according to the EuroNet-PHL-C2 protocol were recruited from 18 sites (5 countries), between January 2017 and September 2021. In 2023, a subset of Dutch participants (aged ≥ 12 years at time of diagnosis) and parents/guardians were surveyed regarding fertility counseling. RESULTS: A total of 101 boys and 104 girls were included. Most post-pubertal boys opted for semen cryopreservation pre-treatment (85% of expected). Invasive FP treatments were occasionally chosen for patients at a relatively low risk of fertility based on scheduled alkylating agent exposure (4/5 testicular biopsy, 4/4 oocyte, and 11/11 ovarian tissue cryopreservation). A total of 17 post-menarchal girls (20%) received GnRH-analogue co-treatment. Furthermore, 33/84 parents and 26/63 patients responded to the questionnaire. Most reported receiving fertility counseling (97%/89%). Statements regarding the timing and content of counseling were generally positive. Parents and patients considered fertility counseling important (94%/87% (strongly agreed) and most expressed concerns about (their child's) fertility (at diagnosis 69%/46%, at present: 59%/42%). CONCLUSION: Systematic fertility counseling is crucial for all pediatric cHL patients and their families. FP treatment should be considered depending on the anticipated risk and patient factors. We encourage the development of a decision aid for FP in pediatric oncology.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012662
003      
CZ-PrNML
005      
20240726151334.0
007      
ta
008      
240723s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers16112109 $2 doi
035    __
$a (PubMed)38893227
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Drechsel, Katja C E $u Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Pediatric Oncology, Cancer Center Amsterdam, 1007 MB Amsterdam, The Netherlands $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands $u Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Medical Center, 1007 MB Amsterdam, The Netherlands
245    10
$a Fertility-Preserving Treatments and Patient- and Parental Satisfaction on Fertility Counseling in a Cohort of Newly Diagnosed Boys and Girls with Childhood Hodgkin Lymphoma / $c KCE. Drechsel, IM. IJgosse, S. Slaats, L. Raasen, FS. Stoutjesdijk, E. van Dulmen-den Broeder, WH. Wallace, A. Beishuizen, D. Körholz, C. Mauz-Körholz, M. Cepelova, A. Uyttebroeck, L. Ronceray, GJL. Kaspers, SL. Broer, MA. Veening, EuroNet-PHL-C2 Study Group
520    9_
$a PURPOSE: The purpose of this study is to evaluate the use of fertility-preserving (FP) treatments and fertility counseling that was offered in a cohort of newly diagnosed children with classical Hodgkin lymphoma (cHL). METHODS: In this observational study, boys and girls with cHL aged ≤ 18 years with scheduled treatment according to the EuroNet-PHL-C2 protocol were recruited from 18 sites (5 countries), between January 2017 and September 2021. In 2023, a subset of Dutch participants (aged ≥ 12 years at time of diagnosis) and parents/guardians were surveyed regarding fertility counseling. RESULTS: A total of 101 boys and 104 girls were included. Most post-pubertal boys opted for semen cryopreservation pre-treatment (85% of expected). Invasive FP treatments were occasionally chosen for patients at a relatively low risk of fertility based on scheduled alkylating agent exposure (4/5 testicular biopsy, 4/4 oocyte, and 11/11 ovarian tissue cryopreservation). A total of 17 post-menarchal girls (20%) received GnRH-analogue co-treatment. Furthermore, 33/84 parents and 26/63 patients responded to the questionnaire. Most reported receiving fertility counseling (97%/89%). Statements regarding the timing and content of counseling were generally positive. Parents and patients considered fertility counseling important (94%/87% (strongly agreed) and most expressed concerns about (their child's) fertility (at diagnosis 69%/46%, at present: 59%/42%). CONCLUSION: Systematic fertility counseling is crucial for all pediatric cHL patients and their families. FP treatment should be considered depending on the anticipated risk and patient factors. We encourage the development of a decision aid for FP in pediatric oncology.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a IJgosse, Irene M $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands $1 https://orcid.org/0009000254762978
700    1_
$a Slaats, Sofie $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands $1 https://orcid.org/0009000504391656
700    1_
$a Raasen, Lisanne $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands $1 https://orcid.org/0009000514866280
700    1_
$a Stoutjesdijk, Francis S $u Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Pediatric Oncology, Cancer Center Amsterdam, 1007 MB Amsterdam, The Netherlands
700    1_
$a van Dulmen-den Broeder, Eline $u Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Pediatric Oncology, Cancer Center Amsterdam, 1007 MB Amsterdam, The Netherlands
700    1_
$a Wallace, W Hamish $u Department of Haematology/Oncology, Royal Hospital for Sick Children, Edinburgh EH16 4TJ, UK
700    1_
$a Beishuizen, Auke $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands $u Department of Haematology/Oncology, Erasmus MC-Sophia Children's Hospital, 3000 CA Rotterdam, The Netherlands $1 https://orcid.org/0000000264821823
700    1_
$a Körholz, Dieter $u Department of Pediatric Hematology and Oncology, Universitätsklinikum Giessen und Marburg GmbH, Standort Giessen-Zentrum für Kinderheilkunde und Jugendmedizin, Feulgenstr. 12, 35392 Giessen, Germany
700    1_
$a Mauz-Körholz, Christine $u Department of Pediatric Hematology and Oncology, Universitätsklinikum Giessen und Marburg GmbH, Standort Giessen-Zentrum für Kinderheilkunde und Jugendmedizin, Feulgenstr. 12, 35392 Giessen, Germany $u Clinic for Paediatric and Adolescent Medicine, Medical Faculty of the Martin-Luther University of Halle, Ernst-Grube-Str. 40, 06120 Halle, Germany $1 https://orcid.org/0000000282058665
700    1_
$a Cepelova, Michaela $u Department of Pediatric Hematology and Oncology, Faculty Hospital Motol and 2nd Medical Faculty, Charles University, V Úvalu 84, 150 06 Prague 5, Czech Republic
700    1_
$a Uyttebroeck, Anne $u Department of Paediatric Haematology and Oncology, KU Leuven, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium $1 https://orcid.org/000000015644424X
700    1_
$a Ronceray, Leila $u Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Kinderspitalgasse 6, A-1090 Wien, Austria
700    1_
$a Kaspers, Gertjan J L $u Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Pediatric Oncology, Cancer Center Amsterdam, 1007 MB Amsterdam, The Netherlands $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands $1 https://orcid.org/0000000177168475
700    1_
$a Broer, Simone L $u Department of Reproductive Medicine & Gynecology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
700    1_
$a Veening, Margreet A $u Emma Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Pediatric Oncology, Cancer Center Amsterdam, 1007 MB Amsterdam, The Netherlands $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
710    2_
$a EuroNet-PHL-C2 Study Group
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 16, č. 11 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38893227 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151326 $b ABA008
999    __
$a ok $b bmc $g 2125437 $s 1224525
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 16 $c 11 $e 20240531 $i 2072-6694 $m Cancers $n Cancers (Basel) $x MED00173178
GRA    __
$a project 257 $p Foundation KiKa
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Možnosti archivace